FRANKFURT (Reuters) - Generic-drug makers Teva and Actavis, backed by Swedish buyout firm EQT, have placed make-or-break bids for German peer Ratiopharm but drug major Pfizer is expected to also be a contender, sources said. Ratiopharm could stay in takeover talks with two or even three bidders, as some bids, which had been due by the end of Friday, are seen ...

Drugmaker Pfizer Inc., well into integrating its new Wyeth unit, posted a 34 percent jump in revenue Wednesday, but $3.2 billion in acquisition and restructuring charges and higher costs across the board weighed down profit. The maker of Viagra and cholesterol fighter Lipitor, which paid $68 billion to get Wyeth's vaccines, biologic drugs and consumer health staples such ...

The stock market retreated from a two-day rally as growth in the nation's service businesses fell short of expectations. The Institute for Supply Management says Wednesday that its index of service activity rose to 50.5 in January from a revised 49.8 in December. The January reading was below analysts' forecast. A disappointing outlook from drug maker Pfizer ...

Drug maker Pfizer Inc., reporting its fourth-quarter results on Wednesday, also updated its financial forecast for 2012, when it faces a revenue cliff as generic competition arrives for its $11.4 billion-a-year cholesterol blockbuster Lipitor. Lipitor is the world's top-selling drug. Buying Wyeth ...